FDA Panel Backs ACAD, AUPH Awaits Data In Q3, CTRV Abuzz

Shares of ACADIA Pharmaceuticals Inc. (ACAD) were up 24% in after-hours on Tuesday, following positive vote from an FDA panel for the company's NUPLAZID for the treatment of psychosis associated with Parkinson's disease.

from RTT - Biotech http://ift.tt/1RJJFXL
via IFTTT